DR ANTHONY MELVIN CRASTO,WorldDrugTracker, helping millions, A 90 % paralysed man in action for you, I am suffering from transverse mylitis and bound to a wheel chair, With death on the horizon, this will not stop me, Only God and death can..........
DR ANTHONY MELVIN CRASTO Ph.D ( ICT, Mumbai), INDIA, worlddrugtracker, 29Yrs Exp. in the feld of Organic Chemistry,Working for GLENMARK PHARMA at Navi Mumbai, INDIA. Serving chemists around the world. Helping them with websites on Chemistry.8 Million hits on google, world acclamation from industry, academia, drug authorities for websites, blogs and educational contributionn, सुकून उतना ही देना प्रभू, जितने से जिंदगी चल जाये।औकात बस इतनी देना,कि औरों का भला हो जाये।...........P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent.
Showing posts with label TD 1607. Show all posts
Showing posts with label TD 1607. Show all posts

Sunday, 12 June 2016

TD 1607

STR1
STR1

TD-1607

Phase I
A glycopeptide-cephalosporin heterodimer potentially for the treatment of gram-positive bacterial infection.
CAS No. 827040-07-3
C95 H109 Cl3 N18 O31 S2, 
Molecular Weight, 2169.47
Vancomycin, 29-​[[[2-​[[6-​[[[1-​[[(6R,​7R)​-​7-​[[(2Z)​-​2-​(2-​amino-​5-​chloro-​4-​thiazolyl)​-​2-​(methoxyimino)​acetyl]​amino]​-​2-​carboxy-​8-​oxo-​5-​thia-​1-​azabicyclo[4.2.0]​oct-​2-​en-​3-​yl]​methyl]​pyridinium-​4-​yl]​methyl]​amino]​-​1,​6-​dioxohexyl]​amino]​ethyl]​amino]​methyl]​-​, inner salt
Vancomycin, 29-[[[2-[[6-[[[1-[[(6R,7R)-7-[[(2Z)-(2-amino-5-chloro-4-thiazolyl)(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]pyridinium-4-yl]methyl]amino]-1,6-dioxohexyl]amino]ethyl]amino]methyl]-, inner salt
  • Originator Theravance
  • Developer Theravance Biopharma
  • Class Antibacterials; Cephalosporins; Glycopeptides
  • Mechanism of Action Cell wall inhibitors
    • Phase I Gram-positive infections

    Most Recent Events

    • 21 Apr 2016 Phase I development is ongoing in USA
    • 01 Jul 2014 Theravance completes a phase I trial in Healthy volunteers in in USA (NCT01949103)
    • 02 Jun 2014 Theravance Biopharma is formed as a spin-off of Theravance
    • CompanyTheravance Biopharma Inc.
      DescriptionGlycopeptide cephalosporin heterodimer antibiotic
      Molecular Target 
      Mechanism of Action 
      Therapeutic ModalitySmall molecule: Combination
      Latest Stage of DevelopmentPhase I
      Standard IndicationGram-negative bacterial infection
      Indication DetailsTreat Gram-positive bacterial infections
PATENT
WO 2005005436
https://www.google.com/patents/WO2005005436A2?cl=en29
The present invention provides novel cross-linked glycopeptide - cephalosporin compounds that are useful as antibiotics. The compounds of this invention have a unique chemical structure in which a glycopeptide group is covalently linked to a pyridinium moiety of a cephalosporin group. Among other properties, compounds of this invention have been found to possess surprising and unexpected potency against Gram-positive bacteria including methicillin-resistant Staphylococci aureus (MRSA). Accordingly, in one aspect, the invention provides a compound of formula I:
Figure imgf000004_0001
 
////////Theravance Biopharma, TD 1607, phase 1, glycopeptide-cephalosporin heterodimer ,  gram-positive bacterial infection
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)